We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Novartis (NVS - Free Report) will announce quarterly earnings of $2.26 per share in its forthcoming report, representing an increase of 9.7% year over year. Revenues are projected to reach $13.9 billion, increasing 8.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Novartis metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to come in at $555.75 million. The estimate points to a change of +4.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Net sales to third parties' will likely reach $14.07 billion. The estimate suggests a change of +9.8% year over year.
Analysts' assessment points toward 'Revenues- Oncology- Kisqali- Total' reaching $1.29 billion. The estimate suggests a change of +64.2% year over year.
Analysts predict that the 'Revenues- Immunology- Cosentyx- Total' will reach $1.72 billion. The estimate indicates a change of +1.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Oncology- Tasigna- US' at $119.43 million. The estimate indicates a year-over-year change of -47.2%.
The consensus estimate for 'Revenues- Oncology- Promacta/Revolade- US' stands at $180.08 million. The estimate points to a change of -41.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- US' should come in at $990.42 million. The estimate suggests a change of -0.3% year over year.
It is projected by analysts that the 'Revenues- Cardiovascular- Entresto- US' will reach $927.94 million. The estimate points to a change of +1.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- ROW' of $149.03 million. The estimate indicates a year-over-year change of -22.8%.
The consensus among analysts is that 'Revenues- Oncology- Tafinlar + Mekinist- ROW' will reach $320.55 million. The estimate indicates a year-over-year change of +4.4%.
Analysts forecast 'Revenues- Oncology- Promacta/Revolade- ROW' to reach $267.72 million. The estimate indicates a year-over-year change of +1.8%.
Based on the collective assessment of analysts, 'Revenues- Immunology- Cosentyx- ROW' should arrive at $734.58 million. The estimate indicates a change of +4.9% from the prior-year quarter.
Novartis shares have witnessed a change of +6.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.2% move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Novartis (NVS - Free Report) will announce quarterly earnings of $2.26 per share in its forthcoming report, representing an increase of 9.7% year over year. Revenues are projected to reach $13.9 billion, increasing 8.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Novartis metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to come in at $555.75 million. The estimate points to a change of +4.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Net sales to third parties' will likely reach $14.07 billion. The estimate suggests a change of +9.8% year over year.
Analysts' assessment points toward 'Revenues- Oncology- Kisqali- Total' reaching $1.29 billion. The estimate suggests a change of +64.2% year over year.
Analysts predict that the 'Revenues- Immunology- Cosentyx- Total' will reach $1.72 billion. The estimate indicates a change of +1.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Oncology- Tasigna- US' at $119.43 million. The estimate indicates a year-over-year change of -47.2%.
The consensus estimate for 'Revenues- Oncology- Promacta/Revolade- US' stands at $180.08 million. The estimate points to a change of -41.2% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- US' should come in at $990.42 million. The estimate suggests a change of -0.3% year over year.
It is projected by analysts that the 'Revenues- Cardiovascular- Entresto- US' will reach $927.94 million. The estimate points to a change of +1.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- ROW' of $149.03 million. The estimate indicates a year-over-year change of -22.8%.
The consensus among analysts is that 'Revenues- Oncology- Tafinlar + Mekinist- ROW' will reach $320.55 million. The estimate indicates a year-over-year change of +4.4%.
Analysts forecast 'Revenues- Oncology- Promacta/Revolade- ROW' to reach $267.72 million. The estimate indicates a year-over-year change of +1.8%.
Based on the collective assessment of analysts, 'Revenues- Immunology- Cosentyx- ROW' should arrive at $734.58 million. The estimate indicates a change of +4.9% from the prior-year quarter.
View all Key Company Metrics for Novartis here>>>Novartis shares have witnessed a change of +6.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.2% move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .